Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bigger Stage Expected For Durbin’s Supplement Industry Criticism

This article was originally published in The Tan Sheet

Executive Summary

One of Congress' most vocal critics of dietary supplements, Sen. Dick Durbin, likely will have greater clout under the Obama presidency, with increased regulation of supplements a likely personal priority

You may also be interested in...



Durbin Requests GAO Inquiry On Supplement Adverse Event Reports

Sen. Durbin says it is unclear how FDA’s adverse event reporting system works to protect consumer safety and asks GAO to investigate the agency’s collection and analysis of dietary supplement AERs.

Durbin Requests GAO Inquiry On Supplement Adverse Event Reports

Sen. Durbin says it is unclear how FDA’s adverse event reporting system works to protect consumer safety and asks GAO to investigate the agency’s collection and analysis of dietary supplement AERs.

Melatonin Snacks Prompt Durbin Questions On Dietary Ingredients in Food

Sen. Dick Durbin wants FDA to issue guidance clarifying the agency's authority to regulate foods containing dietary ingredients as additives.

Related Content

Topics

UsernamePublicRestriction

Register

PS102273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel